The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience

被引:27
作者
Wright, JT
Cushman, WC
Davis, BR
Barzilay, J
Colon, P
Egan, D
Lucente, T
Nwachuku, C
Pressel, S
Leenen, FHH
Frolkis, J
Letterer, R
Walsh, S
Tobin, JN
Deger, GE
机构
[1] Case Western Reserve Univ, Div Hypertens, Clin Hypertens Program, Cleveland, OH 44106 USA
[2] Memphis VAMC, Memphis, TN USA
[3] Univ Texas, Houston, TX USA
[4] Kaiser Permanente, Tucker, GA USA
[5] Ctr Cardiovasc Caguas, Cuguas, PR USA
[6] NHLBI, Bethesda, MD 20892 USA
[7] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[8] Univ Ottawa, Inst Heart, Ottawa, ON, Canada
[9] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[10] Univ Washington, Seattle, WA 98195 USA
[11] Clin Directors Network Inc, New York, NY USA
[12] Madrona Med Grp, Bellingham, WA USA
来源
CONTROLLED CLINICAL TRIALS | 2001年 / 22卷 / 06期
关键词
clinical trial; site recruitment; antihypertensive drug treatment; lipid-lowering drug treatment;
D O I
10.1016/S0197-2456(01)00176-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT ) is a randomized clinical outcome trial of antihypertensive and lipid-lowering therapy in a diverse population (including substantial numbers of women and minorities) of 42,419 high-risk hypertensives aged greater than or equal to 55 years with a planned mean follow-up of 6 years. In this paper, we describe our experience in the identification, recruitment, and selection of clinical centers for this large simple trial capable of meeting the recruitment goals outlined for ALLHAT, and we highlight factors associated with clincal center performance. Over 135,000 recruitment brochures were mailed to physicians. Requests for information and application packets were received from 9351 (6.8%) interested investigators. A total of 1053 completed applications were received and 909 sites (86%) were eventually approved to join the trial. Of the approved sites, 278 either later declined participation or were never activated, and 8 were closed within a year for lack of enrollment. The final 623 randomizing centers exceeded the trial's recruitment goal to enroll at least 40,000 participants into the trial, although the recruitment period was extended 1.5 years longer than planned. Fewer than a quarter of the sites (22.6%) were recruited from academic medical centers or Department of Veterans Affairs Medical Centers. More than half of the sites (54.7%) were private solo or group practices, which contributed 53% of randomized participants. Community health centers comprised about 8% of the ALLHAT sites and 2.9% were part of health maintenance organizations. More than 22% of the principal investigators reported that they had no previous clinical research experience. In summary, ALLHAT was successful in recruiting a diverse group of clinical centers to achieve its patient recruitment goals. (C) Elsevier Science Inc. 2001.
引用
收藏
页码:659 / 673
页数:15
相关论文
共 14 条
[1]  
[Anonymous], BRIT MED J
[2]  
CURB JD, 1991, HYPERTENSION, V17, P35
[3]   RISK FACTOR CHANGES AFTER CESSATION OF INTERVENTION IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL [J].
CUTLER, JA ;
GRANDITS, GA ;
GRIMM, RH ;
THOMAS, HE ;
BILLINGS, JH ;
WRIGHT, NH .
PREVENTIVE MEDICINE, 1991, 20 (02) :183-196
[4]   Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].
Davis, BR ;
Cutler, JA ;
Gordon, DJ ;
Furberg, CD ;
Wright, JT ;
Cushman, WC ;
Grimm, RH ;
LaRosa, J ;
Whelton, PK ;
Perry, HM ;
Alderman, MH ;
Ford, CE ;
Oparil, S ;
Francis, C ;
Proschan, M ;
Pressel, S ;
Black, HR ;
Hawkins, CM .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360
[5]  
Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967
[6]  
MAXWELL MH, 1983, HYPERTENSION, V5, P133
[7]  
NEATON JD, 1987, CONTROL CLIN TRIALS, V8, pS41
[8]  
PETROVITCH H, 1991, HYPERTENSION, V17, P16
[9]   Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [J].
Pressel, S ;
Davis, BR ;
Louis, GT ;
Whelton, P ;
Adrogue, H ;
Egan, D ;
Farber, M ;
Payne, G ;
Probstfield, J ;
Ward, H .
CONTROLLED CLINICAL TRIALS, 2001, 22 (06) :674-686
[10]   REPRESENTATION OF AMERICAN BLACKS IN CLINICAL-TRIALS OF NEW DRUGS [J].
SVENSSON, CK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (02) :263-265